Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

28 févr. 2013 09h25 HE | Source: Repros Therapeutics Inc.

FDA Grants Repros an End of Phase 2 Meeting in Late May to Discuss Proellex(R)-V Phase 3 Study Design

THE WOODLANDS, Texas, Feb. 28, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the FDA has agreed to a Type B meeting scheduled for the last half of May to...
21 févr. 2013 07h00 HE | Source: Repros Therapeutics Inc.

Repros Reports FDA Recommends Pivotal Study ZA-301 of Androxal(R) to be Completed as Originally Planned

FDA recommends all subjects in study ZA-301 complete as per the original protocol FDA accepts additional enrollment into pivotal study ZA-302 SPA for both pivotal trials remains...
11 févr. 2013 09h25 HE | Source: Repros Therapeutics Inc.

Repros Therapeutics Corporate Update

Enrollment in 6 Month Open Label Study Near Completion FDA Meeting Request Submitted Joachim F. Wernicke, Ph.D, M.D., Named Chief Medical Officer Company to Present at BIO CEO in NYC...
28 janv. 2013 06h55 HE | Source: Repros Therapeutics Inc.

Repros Updates Guidance for Top Line Results From First Pivotal Androxal(R) Study to Q3 2013

Timing for NDA submission still planned for mid-2014 Conference call at 8 AM ET on Monday, January 28, 2013 THE WOODLANDS, Texas, Jan. 28, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics...
07 janv. 2013 09h25 HE | Source: Repros Therapeutics Inc.

Repros Reports Core 1-Year DEXA Study Fully Enrolled Ahead of Schedule and Provides Update for Androxal(R) Clinical Program

Enrollment in DEXA study should ensure mid-2014 NDA submission Pivotal studies recruiting on track or faster Data project 83% of men with secondary hypogonadism will be successfully...
03 janv. 2013 09h25 HE | Source: Repros Therapeutics Inc.

Repros' Proellex(R)-V Topline Analysis Suggests 12 Mg Dose Effective and Well Tolerated in Phase 2 for Uterine Fibroids

Company to request end of Phase 2 meeting with FDA during Q1 2013 Consistent efficacy after 4 months of treatment at 12 mg vaginal dose Overall good benefit risk ratio for 12 mg...
13 nov. 2012 17h15 HE | Source: Repros Therapeutics Inc.

Repros Presents Androxal(R) and Proellex(R) Clinical Updates at The Lazard Capital Markets 9th Annual Healthcare Conference

Androxal® on track for mid 2014 NDA submission -- 1st pivotal study fully enrolled -- 6 month and 1 year safety studies on track -- Interim results from 6 month...
13 nov. 2012 16h30 HE | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Reports Third Quarter 2012 Financial Results

THE WOODLANDS, Texas, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2012. Liquidity and...
05 nov. 2012 09h25 HE | Source: Repros Therapeutics Inc.

Repros to Present Androxal(R) and Proellex(R) Clinical Updates at the Lazard Capital Markets 9th Annual Healthcare Conference

THE WOODLANDS, Texas, Nov. 5, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX)today announced the Company will present clinical updates for both its Androxal® and...
08 oct. 2012 09h25 HE | Source: Repros Therapeutics Inc.

FDA Reclassifies Proellex(R) Clinical Hold Status: Repros to Proceed With Phase 2 Study of Low Dose Oral Proellex(R) in the Treatment of Endometriosis

THE WOODLANDS, Texas, Oct. 8, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced the FDA has agreed to a reclassification of the full clinical hold on further oral...

Page précédente

Page suivante